Diana Shipping Inc (DSX)

$1.53 0.01 (0.66%)

19:00 EDT DSX Stock Quote Delayed 30 Minutes

Volume:

Previous Close $1.53

Market Cap 165.13M

PE Ratio -0.30

EPS -5.11

Volume (Avg. Vol.) 133,500

Day's Range 1.48 - 1.54

52-Week Range 1.25 - 4.15

Dividend & Yield N/A (N/A)

DSX Stock Predictions, Articles, and Diana Shipping Inc News

From InvestorPlace
From the Web

Why Rite Aid Corporation (RAD), International Business Machines Corp. (IBM) and Diana Shipping Inc. (DSX) Are 3 of Today’s Worst Stocks

By James Brumley, InvestorPlace Feature Writer Apr 19, 2017

International Business Machines (IBM), Rite Aid (RAD) and Diana Shipping (DSX) shareholders couldn't wait to hear Wednesday's closing bell ring.

How Pfizer Plans to Lead the Industry in Gene Therapies

From Barron's Sep 15, 2020

The drugmaker is eager to recast itself as a high-multiple growth stock. The expected growth will be fired up by 25 product launches, which Pfizer is explaining in two days of online talks.

Interesting SRPT Put And Call Options For January 2023

From Market News Video Sep 14, 2020

Investors in Sarepta Therapeutics Inc (SRPT) saw new options begin trading today, for the January 2023 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 858 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

The Exact Trigger that Indicates Volatility in Sarepta Therapeutics Inc

From Capital Market Laboratories Sep 7, 2020

The Trigger That Turned Sarepta Therapeutics Inc (NASDAQ:SRPT) Volatility into a Winner.

FDA Delays Start of Sarepta’s Gene Therapy Trial. That Doesn’t Faze the Stock’s Bulls.

From Barron's Sep 10, 2020

The delay will cost the company a few months at most, analysts say.

Sarepta Therapeutics Stock Falls On Delay In Quest For Muscular Dystrophy Treatment

From Investor's Business Daily Sep 10, 2020

An FDA request that Sarepta Therapeutics provide for more data on a treatment for Duchenne muscular dystrophy sent SRPT stock falling.

The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Sarepta Flags Potential Delay In Gene Therapy Trial

From Benzinga Sep 10, 2020

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Akouos Inc (NASDAQ: AKUS) Castle Biosciences Inc (NASDAQ: CSTL) ESSA Pharma Inc (NASDAQ: EPIX) Kintara...

Navellier Ratings

Total Grade

Strong Sell